First Trust Advisors LP boosted its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 17.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 42,085 shares of the biopharmaceutical company’s stock after purchasing an additional 6,323 shares during the quarter. First Trust Advisors LP’s holdings in Emergent Biosolutions were worth $1,956,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. LS Investment Advisors LLC boosted its position in Emergent Biosolutions by 183.0% during the fourth quarter. LS Investment Advisors LLC now owns 3,948 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 2,553 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Emergent Biosolutions during the third quarter worth $191,000. GW&K Investment Management LLC purchased a new stake in Emergent Biosolutions during the fourth quarter worth $200,000. SG Americas Securities LLC purchased a new stake in Emergent Biosolutions during the third quarter worth $202,000. Finally, 361 Capital LLC purchased a new stake in Emergent Biosolutions during the third quarter worth $203,000. Institutional investors own 81.54% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, EVP Adam Havey sold 1,898 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $49.50, for a total transaction of $93,951.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Abdun-Nabi sold 21,906 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $47.91, for a total value of $1,049,516.46. Following the transaction, the chief executive officer now owns 226,040 shares in the company, valued at $10,829,576.40. The disclosure for this sale can be found here. Insiders sold 34,798 shares of company stock worth $1,714,330 over the last 90 days. Company insiders own 16.50% of the company’s stock.

Several brokerages have recently issued reports on EBS. ValuEngine upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research downgraded Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 11th. Chardan Capital upped their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Singular Research upped their price objective on Emergent Biosolutions from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Goldman Sachs began coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $52.80.

Shares of EBS stock opened at $53.75 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.85 and a quick ratio of 3.42. Emergent Biosolutions Inc has a 12-month low of $27.94 and a 12-month high of $54.04. The stock has a market capitalization of $2,577.68, a price-to-earnings ratio of 31.80, a PEG ratio of 1.02 and a beta of 1.26.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.04. Emergent Biosolutions had a return on equity of 13.66% and a net margin of 14.73%. The business had revenue of $193.80 million for the quarter, compared to the consensus estimate of $189.96 million. During the same period in the prior year, the business earned $0.74 earnings per share. The business’s revenue was up 27.8% on a year-over-year basis. sell-side analysts anticipate that Emergent Biosolutions Inc will post 2.33 EPS for the current fiscal year.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/emergent-biosolutions-inc-ebs-shares-bought-by-first-trust-advisors-lp/1951951.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.